Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AbbVie’s hepatitis C therapy Maviret recommended for EU approval

AbbVie’s hepatitis C therapy Maviret recommended for EU approval

3rd July 2017

AbbVie has received a recommendation for European regulatory approval of its pan-genotypic hepatitis C therapy Maviret.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has granted a positive opinion recommending marketing authorisation of MAVIRET for the treatment of all major genotypes of chronic hepatitis C virus (HCV) infection.

If approved, Maviret will be made available as a once-daily, ribavirin-free, eight-week option for patients without cirrhosis and who are new to treatment across genotypes 1 to 6, who comprise the majority of people living with HCV.

This positive opinion is supported by clinical trial data that demonstrated a 97.5 percent sustained virologic response rate among patients who were treated with eight weeks of Maviret, with less than 0.4 percent of patients discontinuing treatment.

Dr Michael Severino, executive vice-president for research and development and chief scientific officer at AbbVie, said: "Today's CHMP positive opinion takes us closer to delivering on AbbVie's mission to address continued unmet needs by bringing a new pan-genotypic option to people living with HCV in Europe."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801837476-ADNFCR

We have hundreds of jobs available across the Healthcare industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.